Clinical trial · Observational
Prospective Sample Collection for Cancer of Bladder
Flemish Prospective Clinical and Pathological Database for Urothelial Cancer
NCT03973671CI-TRIAL-00075484ProCaBrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of the Flemish Databank for Urothelial Cancer is to collect clinical and pathological data of patients treated for urothelial cancer (UC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urinary Bladder Neoplasms | Bladder Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- UC patients
- description
- Patients diagnosed with primary or recurrent non-muscle-invasive bladder (NMIBC) cancer. No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines. The clinical (demographic, operative and follow-up) and pathological data of the patients will be collected in a complete anonymous way.
Primary outcomes (1)
- measure
- Progression to MIBC
- timeFrame
- 10 years
- description
- Histopathologically proven muscle-invasive bladder cancer (at least T2 disease) in pathological evaluation of the TURBT specimen
Secondary outcomes (1)
- measure
- Recurrence of NMIBC
- timeFrame
- 5 years
- description
- Clinically (cystoscopically and/or radiologically) proven re-occurence of non-muscle-invasive bladder cancer (Tis, Ta or T1 disease)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * who are aged between 18-90, * who are of male or female sex, * who give their informed consent to collect their clinical and pathological data, * who are planned to undergo TURBT for BC, * who are planned to undergo (salvage) radical cystectomy with or without an extended pelvic lymph node dissection, * who are planned to undergo tumor biopsy (from primary or metastatic tumor), * who are planned to undergo radical nephroureterectomy ± partial cystectomy or segmental ureterectomy, with or without a lymph node dissection, * who are planned to undergo endoscopic tumor biopsy or resection, * from whom metastases will be surgically removed. Exclusion Criteria: * patients who do not give their informed consent to collect their clinical and pathological data, * patients who withdraw their informed consent to use their clinical and pathological data, * patients who refuse the planned treatment, * women who are pregnant or have suspicion of pregnancy.
References
Publications (0)
Data not yet available
No reference posted for this study.